Literature DB >> 20797434

Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol.

Päivi Lehtonen1, Taina Sten, Olli Aitio, Mika Kurkela, Katariina Vuorensola, Moshe Finel, Risto Kostiainen.   

Abstract

O-Desmethyltramadol, the active metabolite of analgesic tramadol, is metabolised through glucuronidation. The present study was conducted to identify the human UDP-glucuronosyltransferases (UGTs) that catalyse the glucuronidation of O-desmethyltramadol, a racemic mixture of 1R,2R- and 1S,2S-enantiomers. We developed a fast and selective liquid chromatography-mass spectrometry method to separate, analyse and quantify the diastereomeric phenolic O-glucuronides of O-desmethyltramadol. To quantify O-desmethyltramadol glucuronidation, we biosynthesised both phenolic O-glucuronides of O-desmethyltramadol and verified their structure by mass spectrometry and nuclear magnetic resonance spectroscopy. Subsequently, the 16 human UGTs of subfamilies 1A and 2B were screened for O-desmethyltramadol glucuronidation activity. UGTs 1A7-1A10 exhibited a strict stereoselectivity, exclusively glucuroniding the 1R,2R-enantiomer. Similar though not strict enantioselectivity was exhibited by UGT2B15. UGT2B7, on the other hand, glucuronidated both O-desmethyltramadol enantiomers, with slight preference for 1S,2S-O-desmethyltramadol. Enzyme kinetic parameters were determined for the most active UGTs, 1A8 and 2B7. The apparent K(m) or S(50) values were high: 1.2mM±0.23 for 1R,2R-O-desmethyltramadol with UGT1A8 and 1.84±1.2 and 4.6±2.0mM for 1S,2S- and 1R,2R-O-desmethyltramadol enantiomers with UGT2B7, respectively. Glucuronidation analyses of O-desmethyltramadol with human liver microsomes exhibited stereoselectivity, favouring the 1S,2S-O-desmethyltramadol over 1R,2R-O-desmethyltramadol and yielding 62.4 and 24.6pmol/mg/min, respectively. In intestinal microsomes, on the other hand, the two enantiomers were glucuronidated at similar rates, about 6pmol/mg/min. The results shed new light on both tramadol metabolism and the substrate selectivity of the human UGTs.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797434     DOI: 10.1016/j.ejps.2010.08.005

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  13 in total

1.  PharmGKB summary: tramadol pathway.

Authors:  Li Gong; Ulrike M Stamer; Mladen V Tzvetkov; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-07       Impact factor: 2.089

2.  Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.

Authors:  John A Zebala; Shawn L Searle; Lynn R Webster; Matt S Johnson; Aaron D Schuler; Dean Y Maeda; Stuart J Kahn
Journal:  J Pain       Date:  2019-04-18       Impact factor: 5.820

Review 3.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

4.  Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

Authors:  Valerie P O'Brien; Kristin Bokelmann; Jacqueline Ramírez; Karoline Jobst; Mark J Ratain; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  J Pharmacol Exp Ther       Date:  2013-08-06       Impact factor: 4.030

5.  Oral Coadministration of Fluconazole with Tramadol Markedly Increases Plasma and Urine Concentrations of Tramadol and the O-Desmethyltramadol Metabolite in Healthy Dogs.

Authors:  Tania E Perez Jimenez; Butch Kukanich; Hyun Joo; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  Drug Metab Dispos       Date:  2018-10-26       Impact factor: 3.922

6.  Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.

Authors:  Tao Long; Rodrigo Cristofoletti; Brian Cicali; Veronique Michaud; Pamela Dow; Jacques Turgeon; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2021-09-20       Impact factor: 2.860

7.  The effects of tramadol on norepinephrine and MHPG releasing in locus coeruleus in formalin test in rats: a brain stereotaxic study.

Authors:  Mohammad Ali Mobasher; Javad Sajedianfard; Akram Jamshidzadeh; Naser Naghdi; Mohammad Mehdi Namvaran
Journal:  Iran J Basic Med Sci       Date:  2014-06       Impact factor: 2.699

8.  Pharmacogenomic considerations in opioid analgesia.

Authors:  Pascal H Vuilleumier; Ulrike M Stamer; Ruth Landau
Journal:  Pharmgenomics Pers Med       Date:  2012-08-23

Review 9.  Tramadol Extended-Release for the Management of Pain due to Osteoarthritis.

Authors:  Chiara Angeletti; Cristiana Guetti; Antonella Paladini; Giustino Varrassi
Journal:  ISRN Pain       Date:  2013-09-04

Review 10.  When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children.

Authors:  Frédérique Rodieux; Laszlo Vutskits; Klara M Posfay-Barbe; Walid Habre; Valérie Piguet; Jules A Desmeules; Caroline F Samer
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.